A Phase 3 interventional study of Valsartan/hydrochlorothiazide (HCTZ) and Valsartan/amlodipine in Hypertension, sponsored by Novartis. Completed at 5 sites in India. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2010-09-27.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
The purpose of this study is to determine potential pharmacokinetic drug-drug interaction when three drugs (valsartan, amlodipine, and hydrochlorothiazide) are co-administered.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 111 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: Valsartan/hydrochlorothiazide (HCTZ)
Drug: Valsartan/amlodipine
Drug: Amlodipine/hydrochlorothiazide(HCTZ)
Drug: Valsartan/amlodipine/hydrochlorothiazide(HCTZ)
Potential drug interaction and effect on blood level of drugs when co-administered for 17 days
Safety and tolerability of co-administered assessed by capturing adverse events and safety laboratory
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis